🔗 Share this article

The first new treatments for gonorrhoea in a generation are being described as a "significant breakthrough" in the fight against increasingly resistant strains of the bacteria, according to health experts.

A Worldwide Public Health Issue

The sexually transmitted infection are escalating globally, with figures suggesting more than 82 million instances each year. Particularly high rates are observed in Africa and nations within the World Health Organization's designated area, which spans from China and Mongolia to New Zealand. Within England, cases have reached a record high, while figures across Europe in 2023 were triple the level compared to the rates from 2014.

“The clearance of new treatments for gonorrhoea is an important and timely advancement in the context of growing infection rates, increasing antimicrobial resistance and the highly restricted therapeutic options currently available.”

Medical experts are particularly alarmed about the surge in drug-resistant strains. The global health body has designated it as a "high-priority threat". Recent surveillance revealed that the effectiveness of primary antibiotics like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

A Pair of Novel Treatment Options Receive Authorization

One new antibiotic, also known as a brand name, was authorized by the US Food and Drug Administration in mid-December for treating gonorrhoea. This disease can lead to major issues, including the inability to conceive. Experts hope that specific application of this new drug will help delay the development of resistance.

Gepotidacin, developed by the pharmaceutical company GlaxoSmithKline, gained clearance in the same week. This drug, which is also used to treat urinary tract infections, was demonstrated in studies to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Approach to Creation

Zoliflodacin was the result of a unique collaborative effort for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the drug firm Innoviva to develop it.

“This approval signifies a major breakthrough in the therapy of superbug gonorrhoea, which previously has been outpacing our drug pipeline.”

Clinical Trial Data and Global Access

Based on results detailed in a major medical journal, the new drug successfully treated the vast majority of genital gonorrhoea infections. This establishes an comparable level with the current standard treatment, which combines a dual-drug approach. The trial enrolled hundreds of volunteers from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its unique model, the non-profit has the authority to register and commercialise the drug in a wide range of low-income and middle-income countries.

Doctors on the front lines have shared positive views. Access to a one-pill regimen like this is hailed as a "game-changer" for gonorrhoea control. This is viewed as vital to alleviate the strain of the illness for people and to halt the transmission of untreatable gonorrhoea worldwide.